TissUse
Private Company
Funding information not available
Overview
TissUse is a pioneering German biotech firm that has created the HUMIMIC 'Multi-Organ-Chip' platform, a groundbreaking human-on-a-chip technology. This platform enables the interconnection of up to four human miniature organs on a single chip, offering a more predictive alternative to animal models for drug and chemical safety evaluation. The company operates through a hybrid business model, offering both proprietary products (the HUMIMIC chip systems) and high-value contract research services to pharmaceutical, cosmetic, and chemical industries. As a private, growth-stage company, TissUse is positioned at the forefront of the emerging organ-on-a-chip market, aiming to reduce drug development costs and failure rates.
Technology Platform
HUMIMIC 'Multi-Organ-Chip' platform, a proprietary human-on-a-chip system that interconnects up to four miniature human organ models in a microfluidic circuit for predictive pharmacology and toxicology testing.
Opportunities
Risk Factors
Competitive Landscape
TissUse operates in the competitive and fast-growing organ-on-a-chip market. Key competitors include Emulate, Inc. (US), Mimetas (Netherlands), CN Bio Innovations (UK), and Hesperos (US). Its primary competitive differentiation is its patented multi-organ integration capability (up to four organs), focusing on systemic interaction studies, whereas some competitors specialize in single-organ or simpler two-organ models.